Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Circassia's ToleroMune hay fever vaccine showed improvement in patient's allergy symptoms in a randomized, double-blind, placebo-controlled Phase II trial as compared to placebo.
Subscribe to our email newsletter
The results from the trial demonstrated that the treatment reduced allergic symptoms in patients’ eyes by up to 30% more than placebo.
The trial which involved around 50 patients with hay fever, was conducted in Quebec, Canada.
In the trial, the patients received four doses from one of five different treatment regimes over a 12-week period.
Circassia CEO Steve Harris said their clinical data give them the confidence to proceed with the final phase II testing of their hay fever treatment.